Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $80.00 at Morgan Stanley

Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price objective boosted by Morgan Stanley from $77.00 to $80.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other analysts have also recently commented on CRNX. The Goldman Sachs Group increased their price target on shares of Crinetics Pharmaceuticals from $35.00 to $40.00 and gave the company a “neutral” rating in a research note on Friday, September 26th. Wall Street Zen upgraded shares of Crinetics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research report on Wednesday, October 8th. Robert W. Baird upped their price objective on Crinetics Pharmaceuticals from $58.00 to $62.00 and gave the company an “outperform” rating in a research note on Friday, September 26th. Finally, JMP Securities lifted their target price on Crinetics Pharmaceuticals from $86.00 to $143.00 and gave the stock a “market outperform” rating in a research note on Friday, September 26th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $77.82.

Crinetics Pharmaceuticals Stock Performance

Shares of NASDAQ CRNX opened at $45.95 on Tuesday. The stock has a 50 day moving average price of $45.55 and a 200 day moving average price of $38.15. The stock has a market capitalization of $4.36 billion, a PE ratio of -10.14 and a beta of 0.20. Crinetics Pharmaceuticals has a 52 week low of $24.10 and a 52 week high of $57.99.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.11). The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.39 million. During the same quarter in the prior year, the company posted ($0.96) EPS. As a group, research analysts forecast that Crinetics Pharmaceuticals will post -3.73 EPS for the current year.

Insiders Place Their Bets

In related news, insider Dana Pizzuti sold 5,000 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $42.66, for a total transaction of $213,300.00. Following the completion of the sale, the insider directly owned 66,270 shares of the company’s stock, valued at approximately $2,827,078.20. This trade represents a 7.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Headlands Technologies LLC bought a new position in Crinetics Pharmaceuticals during the second quarter worth about $30,000. Farther Finance Advisors LLC increased its holdings in shares of Crinetics Pharmaceuticals by 523.7% during the third quarter. Farther Finance Advisors LLC now owns 842 shares of the company’s stock worth $35,000 after purchasing an additional 707 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Crinetics Pharmaceuticals in the second quarter valued at approximately $45,000. Penserra Capital Management LLC bought a new stake in shares of Crinetics Pharmaceuticals in the second quarter valued at approximately $48,000. Finally, Covestor Ltd grew its position in Crinetics Pharmaceuticals by 23,983.3% during the third quarter. Covestor Ltd now owns 1,445 shares of the company’s stock worth $60,000 after buying an additional 1,439 shares in the last quarter. Institutional investors own 98.51% of the company’s stock.

Key Crinetics Pharmaceuticals News

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

• Positive Sentiment: Strong commercial launch — Crinetics reported unaudited, preliminary PALSONIFY U.S. net product revenue of over $5M in Q4 2025 with >200 enrollment forms, evidence of early market uptake that supports near-term revenue prospects. Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results
• Positive Sentiment: Encouraging Phase 2 data for atumelnant — Cohort 4/topline Phase 2 results showed a 67% mean reduction in androstenedione and enabled 88% of participants to reduce glucocorticoid dosing to physiologic replacement, with no hepatic transaminase signals reported — strengthens the drug’s clinical profile and long‑term pipeline value. Atumelnant Phase 2 Results
• Positive Sentiment: Analyst support — Morgan Stanley raised its price target to $80 and maintained an “overweight” rating, signaling strong sell-side confidence and providing potential upside relative to current levels. Analyst Price Target Raise
• Neutral Sentiment: Investor communications and coverage — Management hosted investor calls and multiple transcripts/coverage (Seeking Alpha, Yahoo/press pick‑ups) are disseminating details on launch progress and trial design, improving transparency but not immediately changing fundamentals. Investor Call / Transcript
• Negative Sentiment: Planned $350M equity offering — Crinetics announced a proposed underwritten public offering of $350M (plus a 30‑day option for $52.5M) of common stock, which is dilutive and likely the main driver of intraday selling pressure despite the positive news flow. Proposed Public Offering

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.